DiogenX is a preclinical stage biotechnology company based in Marseille, France, with additional research facilities in Nice. Founded in 2019, DiogenX specializes in developing pancreatic beta-cell modulators aimed at treating Type 1 and Type 2 diabetes. The company's primary focus is on creating a candidate molecule that regenerates pancreatic insulin-producing cells in diabetic patients, which has the potential to improve both quality of life and survival rates. This innovative approach to therapy was initially discovered in the laboratory of Dr. Patrick Collombat at Inserm, CNRS, and Nice University, positioning DiogenX as a pioneer in beta-cell regeneration for diabetes treatment.
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.
Importantly, the approach improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
Good Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, founded in 2016. The company specializes in the development of biotherapeutics and self-regulating drugs that deliver therapeutic effects precisely when and where needed. Its innovative approach involves creating context-dependent protein drugs that can sense biomarkers and respond accordingly, thus minimizing systemic toxicity while maintaining therapeutic efficacy. Good Therapeutics employs an algorithm designed for allosterically-regulated proteins, which alter their shape upon binding with specific biomarkers or metabolites, activating their therapeutic functions. The company's primary focus is on applications within immuno-oncology, aiming to enhance treatment outcomes while ensuring patient safety.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
Jasper Therapeutics, Inc. is a biotechnology company based in Menlo Park, California, that specializes in developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. Founded in 2018, the company is focused on creating safer and more effective conditioning agents to enhance the efficacy of stem cell transplants and gene therapies. Its lead product, JSP191, is a humanized monoclonal antibody currently in clinical development, designed to act as a conditioning agent by clearing hematopoietic stem cells from bone marrow. JSP191 targets the CD117 receptor, which is expressed on hematopoietic stem and progenitor cells, thereby facilitating safer transplant procedures and potentially broadening the application of curative therapies.
We're a digital healthcare company on a mission to enhance patients outcome by helping doctors and companies make better decisions through the generation of reliable synthetic data and by developing decision support systems
Soteria Biotherapeutics, Inc., founded in 2018 and based in San Francisco, California, specializes in the development of innovative immunotherapies for cancer treatment. The company is focused on creating next-generation conditionally active bispecific T-cell engaging antibodies aimed at addressing solid tumors. Utilizing its proprietary T-LITE™ platform, Soteria enables the small molecule-dependent activation of these bispecific antibody therapies. This approach allows for safer and more effective treatments, characterized by pulsatile activity that minimizes side effects and permits higher dosing levels for patients. Through its advancements, Soteria Biotherapeutics strives to improve the therapeutic options available for cancer patients.
At Arch Oncology, they are aiming high to discover and develop new antibody therapeutics to treat patients living with cancer. They are committed to advancing antibodies with best-in-class potential.Their next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class.
Entrada Therapeutics, Inc., a biotechnology company, engages in the treatment of diseases through the intracellular delivery of biologic. The company enables intracellular delivery of proteins, peptides, and nucleic acids and allows development of programs across intracellular target classes. Its Intracellular enzyme replacement therapy (IC-ERT) is a medical treatment that corrects an enzyme deficiency in the cell, Protein-Protein Interaction Inhibitors. The company was founded in 2016 and is based in Boston, Massachusetts.
GenMark Diagnostics is a molecular diagnostics company based in Carlsbad, California, specializing in the development and commercialization of its proprietary eSensor electrochemical detection technology. This technology enables the detection of multiple biomarkers from a single sample, facilitating rapid and accurate diagnostic testing. The company offers the ePlex instrument and associated respiratory pathogen panels, which allow for automated nucleic acid extraction and amplification, yielding results within 30 minutes. GenMark's XT-8 System, which has received FDA clearance, supports a wide range of molecular tests through its compact workstation and disposable test cartridges. This system is designed for use in hospitals and reference laboratories and can process up to 24 independent tests simultaneously. Additionally, GenMark is advancing its next-generation AD-8 System, which aims to further streamline the testing process by integrating DNA amplification with eSensor technology. The company's products are marketed through direct sales and specialized service organizations across the United States and Europe.
Enthera S.r.l. is an Italian biotechnology company established in 2016, based in Milan, and operates as a subsidiary of BiovelocITA S.r.l. The company focuses on developing innovative biologics aimed at treating diabetes and its related gastrointestinal complications, particularly enteropathy, as well as other intestinal disorders that share similar biological pathways. Enthera's research is centered on monoclonal antibody discovery and biotherapeutics that target mechanisms involved in cell apoptosis in the gut, pancreas, and other organs. By addressing these pathways, Enthera aims to provide effective treatments for underserved autoimmune conditions, thereby contributing to advancements in the management of type 1 diabetes and inflammatory bowel disease. The company's name reflects its mission, combining the terms "entero," relating to the intestine, and "therapy."
Enliven Therapeutics is a clinical-stage precision oncology company dedicated to the discovery and development of innovative small molecule therapies aimed at enhancing patient outcomes. The company focuses on addressing critical challenges in cancer treatment, such as tolerability, combinability, resistance, and disease progression, particularly in the context of brain metastases. Enliven's lead product candidates include ELVN-001, a selective small molecule kinase inhibitor targeting the BCR-ABL gene fusion associated with chronic myeloid leukemia, and ELVN-002, an irreversible HER2 inhibitor designed to penetrate the central nervous system and target both wild type HER2 and related variants. Through its advanced discovery process, Enliven Therapeutics aims to create first-in-class therapies that improve the quality of life for patients facing cancer.
Palladio Biosciences, Inc. is a biotechnology company focused on developing transformative medicines for orphan diseases of the kidney. Founded in 2015 and based in Horsham, Pennsylvania, the company is in the clinical stage and specializes in therapeutics aimed at renal diseases, particularly polycystic kidney disease (PKD). One of its key developments is Lixivaptan, a selective vasopressin V2 receptor antagonist designed to treat PKD, a life-threatening genetic disorder characterized by the growth of numerous fluid-filled cysts in the kidneys. Palladio Biosciences aims to provide innovative treatment options that can help prevent the progression of kidney diseases.
Inflazome Ltd. is a biotechnology company based in Dublin, Ireland, founded in 2016, that focuses on developing orally available drugs for inflammatory diseases by targeting the inflammasome. The company's innovative approach aims to block inflammasome signals, addressing the underlying causes of inflammation. Inflazome's portfolio includes treatments for a range of conditions, such as orphan diseases like Muckle-Wells syndrome and familial cold autoinflammatory syndrome, as well as chronic inflammatory disorders affecting the central nervous system, including Alzheimer's, Parkinson's, and multiple sclerosis. The company also targets systemic inflammatory diseases like cardiovascular and gastrointestinal issues, and explores applications in oncology and dermatology. Inflazome operates as a subsidiary of Roche Holding AG.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.
Stratos Genomics, Inc., a DNA sequencing technology company, develops sequencing by expansion, a single-molecule detection process for genome sequencing and targeted oncology panels. It enables genome sequencing using nanopore technology, wherein a device transits through the nanopore and a distinct electrical signal of each base reporter is identified. The company was founded in 2007 and is based in Seattle, Washington. As of May 20, 2020, Stratos Genomics, Inc. operates as a subsidiary of Roche Holding AG.
Good Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, founded in 2016. The company specializes in the development of biotherapeutics and self-regulating drugs that deliver therapeutic effects precisely when and where needed. Its innovative approach involves creating context-dependent protein drugs that can sense biomarkers and respond accordingly, thus minimizing systemic toxicity while maintaining therapeutic efficacy. Good Therapeutics employs an algorithm designed for allosterically-regulated proteins, which alter their shape upon binding with specific biomarkers or metabolites, activating their therapeutic functions. The company's primary focus is on applications within immuno-oncology, aiming to enhance treatment outcomes while ensuring patient safety.
Zikani Therapeutics, Inc. develops and commercializes therapeutics for patients with limited treatment options. It offers TURBO-ZM, a platform to develop novel ribosome modulating agents (RMAs) for the treatment of cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Zikani Therapeutics, Inc. was formerly known as Macrolide Pharmaceuticals, Inc. and changed its name to Zikani Therapeutics, Inc. in February 2015. Zikani Therapeutics, Inc. was incorporated in 2014 and is based in Watertown, Massachusetts.
Pandion Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapeutics for autoimmune diseases. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials to address various autoimmune and inflammatory conditions. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to facilitate tissue-selective immunomodulation in the gastrointestinal tract. PT001 combines a PD-1 agonist with a tether module that binds to mucosal vascular addressing cell adhesion molecule (MAdCAM), while PT002 merges an IL-2 mutein effector with a MAdCAM-binding module. The company has also established a collaboration with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. Headquartered in Watertown, Massachusetts, Pandion Therapeutics aims to create effective and safe treatments to improve patient outcomes in the field of autoimmune disorders.
Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains causing significant invasive pneumococcal disease and antibiotic resistance; VAX-A1, a conjugate vaccine candidate for protection against subtypes of Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was founded in 2013 and is headquartered in Foster City, California.
Jasper Therapeutics, Inc. is a biotechnology company based in Menlo Park, California, that specializes in developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. Founded in 2018, the company is focused on creating safer and more effective conditioning agents to enhance the efficacy of stem cell transplants and gene therapies. Its lead product, JSP191, is a humanized monoclonal antibody currently in clinical development, designed to act as a conditioning agent by clearing hematopoietic stem cells from bone marrow. JSP191 targets the CD117 receptor, which is expressed on hematopoietic stem and progenitor cells, thereby facilitating safer transplant procedures and potentially broadening the application of curative therapies.
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in South San Francisco, California. The company specializes in developing innovative therapeutics to address unmet medical needs in viral and liver diseases, particularly targeting chronic hepatitis B (CHB) and non-alcoholic steatohepatitis (NASH). Its lead drug candidate, ALG-010133, is a synthetic oligonucleotide currently undergoing Phase I clinical trials for CHB. Aligos is also advancing several other candidates, including ALG-000184, a capsid assembly modulator for CHB; ALG-020572, an oligonucleotide for CHB; ALG-125097, an siRNA drug candidate for CHB; and ALG-055009, a small molecule THR-ß agonist for NASH. The company's strategy leverages the extensive expertise of its team in liver disease and viral hepatitis to develop targeted antiviral therapies and expedite its drug development pipeline.
Jasper Therapeutics, Inc. is a biotechnology company based in Menlo Park, California, that specializes in developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. Founded in 2018, the company is focused on creating safer and more effective conditioning agents to enhance the efficacy of stem cell transplants and gene therapies. Its lead product, JSP191, is a humanized monoclonal antibody currently in clinical development, designed to act as a conditioning agent by clearing hematopoietic stem cells from bone marrow. JSP191 targets the CD117 receptor, which is expressed on hematopoietic stem and progenitor cells, thereby facilitating safer transplant procedures and potentially broadening the application of curative therapies.
Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule, tumor-agnostic therapies. The company's lead product candidate, BDTX-189, is designed to inhibit specific mutations in ErbB kinases, including the epidermal growth factor receptor. Additionally, Black Diamond is advancing a pipeline of allosteric-EGFR mutation inhibitors and other early-stage programs targeting allosteric mutations in kinases associated with cancer and rare genetic diseases. The company employs a technology platform known as Mutation-Allostery-Pharmacology, which aims to address undrugged mutations in patients with genetically defined cancers. Founded in 2014 and based in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its rebranding in 2018.
Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic diseases, such as idiopathic pulmonary fibrosis and myelofibrosis, as well as retinal fibrovascular diseases like age-related macular degeneration and diabetic retinopathy. The company has created a drug discovery platform that targets monocyte-derived cell populations involved in fibrotic, inflammatory, and autoimmune diseases. By addressing the source of abnormal immune responses, Promedior aims to promote tissue healing while minimizing systemic side effects associated with existing therapies. Its main products include PRM-151, a recombinant form of human pentaxin-2 protein for intravenous injection, and PRM-167, designed for intravitreal delivery. Promedior was previously known as Fibrotix, Inc. and has been a subsidiary of Roche Holding AG since February 2020.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
Purigen Biosystems' innovative products offer a truly transformative solution for DNA and RNA purification. Our proprietary approach uses isotachophoresis to separate nucleic acids freely in solution without binding or stripping from a physical surface. Because of this, our technology is agnostic to nucleic acid size or sequence and delivers unbiased results ― even from the more challenging sample types like FFPE tissue or low cell counts. Our Ionic Purification System and Kits combine to provide researchers with a fast, efficient and effective alternative for automated nucleic acid purification.
At Arch Oncology, they are aiming high to discover and develop new antibody therapeutics to treat patients living with cancer. They are committed to advancing antibodies with best-in-class potential.Their next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class.
MacuLogix, Inc. specializes in the diagnosis, monitoring, and treatment of age-related macular degeneration (AMD), a leading cause of blindness. The company offers the AdaptDx, a fully automated dark adaptometer designed to aid eye care professionals in detecting and tracking AMD at its earliest stages, potentially up to three years before it becomes visible. This early detection capability allows for timely intervention, which can help prevent vision loss. MacuLogix markets its products through distributors in the United States and internationally, as well as online, to ensure accessibility for healthcare providers. Founded in 2008 and based in Harrisburg, Pennsylvania, MacuLogix is committed to leveraging the science of dark adaptation to combat preventable blindness associated with AMD.
Spark Therapeutics, Inc. is dedicated to developing gene therapy products aimed at treating debilitating genetic diseases. The company is known for LUXTURNA, a treatment for patients with biallelic RPE65 mutation-associated retinal dystrophy, and has an extensive pipeline that includes candidates like SPK-8011 and SPK-8016 for hemophilia, SPK-7001 for choroideremia, and SPK-9001 for hemophilia B. Additionally, Spark is exploring liver-directed gene therapies such as SPK-3006 for Pompe disease and has programs targeting neurodegenerative diseases, including Huntington's disease and a form of Batten disease. Spark Therapeutics also engages in collaborations, notably with Pfizer for the SPK-FIX program for hemophilia B, and has a licensing agreement with Novartis for the commercialization of LUXTURNA outside the United States. Established in 2013 and based in Philadelphia, Spark Therapeutics operates as a subsidiary of Roche Holding AG and leverages a proprietary manufacturing platform to support its clinical studies across various therapeutic areas.
Good Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, founded in 2016. The company specializes in the development of biotherapeutics and self-regulating drugs that deliver therapeutic effects precisely when and where needed. Its innovative approach involves creating context-dependent protein drugs that can sense biomarkers and respond accordingly, thus minimizing systemic toxicity while maintaining therapeutic efficacy. Good Therapeutics employs an algorithm designed for allosterically-regulated proteins, which alter their shape upon binding with specific biomarkers or metabolites, activating their therapeutic functions. The company's primary focus is on applications within immuno-oncology, aiming to enhance treatment outcomes while ensuring patient safety.
Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule, tumor-agnostic therapies. The company's lead product candidate, BDTX-189, is designed to inhibit specific mutations in ErbB kinases, including the epidermal growth factor receptor. Additionally, Black Diamond is advancing a pipeline of allosteric-EGFR mutation inhibitors and other early-stage programs targeting allosteric mutations in kinases associated with cancer and rare genetic diseases. The company employs a technology platform known as Mutation-Allostery-Pharmacology, which aims to address undrugged mutations in patients with genetically defined cancers. Founded in 2014 and based in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its rebranding in 2018.
Entrada Therapeutics, Inc., a biotechnology company, engages in the treatment of diseases through the intracellular delivery of biologic. The company enables intracellular delivery of proteins, peptides, and nucleic acids and allows development of programs across intracellular target classes. Its Intracellular enzyme replacement therapy (IC-ERT) is a medical treatment that corrects an enzyme deficiency in the cell, Protein-Protein Interaction Inhibitors. The company was founded in 2016 and is based in Boston, Massachusetts.
Tusk Therapeutics Ltd develops therapeutic antibodies for the treatment of cancer. The company develops immuno-oncology drugs that work for the depletion of regulatory T-cells (Tregs). The company's products include CD25, a Treg depleting agent and CD38, an immune checkpoint which inhibits immunosuppressive cells. The company was founded in 2014 and is based in Stevenage, United Kingdom. As of September 28, 2018, Tusk Therapeutics Ltd operates as a subsidiary of F. Hoffmann-La Roche Ltd.
Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.
Biodesy has developed a unique and highly sensitive means of detecting conformational change in proteins and other biological molecules. Our technology, based on a phenomenon called ‘second-harmonic generation’ (SHG), can monitor structural change at any site within a protein, in real time.
At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.
Atterocor, Inc. focuses on research and development of therapeutics for adrenal disease. Atterocor, Inc. was incorporated in 2012 and is based in Ann Arbor, Michigan.
Care Innovations specializes in technology-based healthcare management services that facilitate connections between individuals and caregivers. The company focuses on collecting, aggregating, and analyzing data to deliver actionable insights that link providers, payers, caregivers, and consumers. By enhancing the care continuum within the home, Care Innovations aims to support individuals in living independently while also contributing to a reduction in healthcare costs.
Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains causing significant invasive pneumococcal disease and antibiotic resistance; VAX-A1, a conjugate vaccine candidate for protection against subtypes of Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was founded in 2013 and is headquartered in Foster City, California.
CiVi Biopharma is a clinical-stage biotechnology company focused on developing innovative therapies for cardiovascular and metabolic diseases, particularly those with significant unmet medical needs. The company is advancing multiple assets in its pipeline, including Intravenous Iloprost, which is currently undergoing Phase 3 trials for the treatment of Systemic Sclerosis. By concentrating on both cardiovascular and rare diseases, CiVi Biopharma aims to provide valuable therapeutic options that enhance patient care and improve health outcomes.
Zikani Therapeutics, Inc. develops and commercializes therapeutics for patients with limited treatment options. It offers TURBO-ZM, a platform to develop novel ribosome modulating agents (RMAs) for the treatment of cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Zikani Therapeutics, Inc. was formerly known as Macrolide Pharmaceuticals, Inc. and changed its name to Zikani Therapeutics, Inc. in February 2015. Zikani Therapeutics, Inc. was incorporated in 2014 and is based in Watertown, Massachusetts.
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.
Importantly, the approach improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.
IDEAYA Biosciences is an oncology-focused biotechnology company based in South San Francisco, California, dedicated to the discovery and development of targeted therapeutics for genetically defined patient populations. The company specializes in precision medicine using molecular diagnostics and synthetic lethality approaches to address cancer treatment. Its lead product candidate, IDE196, is a protein kinase C inhibitor currently undergoing Phase 1/2 clinical trials for cancers associated with GNAQ or GNA11 gene mutations. IDEAYA's preclinical pipeline includes programs targeting various mechanisms related to DNA damage and repair, such as MAT2A for tumors with MTAP deletions, Pol-theta for homologous recombination deficiency, and PARG for BRCA2 mutation context. The company collaborates with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase, while also engaging in partnerships for clinical trials with Pfizer and GlaxoSmithKline. Founded in 2015, IDEAYA aims to advance innovative therapies for enhancing immunotherapy responses and improving patient outcomes in oncology.
Flatiron Health, Inc. is a healthcare technology company that specializes in oncology, focusing on enhancing cancer research and patient care. The company has developed a data platform that integrates and organizes clinical and financial information from electronic medical records and billing systems. This platform, known as OncologyCloud, provides valuable analytics for cancer care providers and life sciences organizations, enabling them to track treatment patterns, monitor adherence to guidelines, and identify suitable candidates for clinical trials in real-time. Flatiron Health also offers additional tools such as OncoCloud for community oncology practices, Flatiron Assist for clinical decision support, and OncoEMR to assist providers in meeting oncology care model requirements. The company collaborates with over 280 community cancer practices, several major academic research centers, and prominent oncology companies. Founded in 2012 and based in New York, Flatiron Health operates as a subsidiary of Roche Holding AG.
Pandion Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapeutics for autoimmune diseases. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials to address various autoimmune and inflammatory conditions. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to facilitate tissue-selective immunomodulation in the gastrointestinal tract. PT001 combines a PD-1 agonist with a tether module that binds to mucosal vascular addressing cell adhesion molecule (MAdCAM), while PT002 merges an IL-2 mutein effector with a MAdCAM-binding module. The company has also established a collaboration with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. Headquartered in Watertown, Massachusetts, Pandion Therapeutics aims to create effective and safe treatments to improve patient outcomes in the field of autoimmune disorders.
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in South San Francisco, California. The company specializes in developing innovative therapeutics to address unmet medical needs in viral and liver diseases, particularly targeting chronic hepatitis B (CHB) and non-alcoholic steatohepatitis (NASH). Its lead drug candidate, ALG-010133, is a synthetic oligonucleotide currently undergoing Phase I clinical trials for CHB. Aligos is also advancing several other candidates, including ALG-000184, a capsid assembly modulator for CHB; ALG-020572, an oligonucleotide for CHB; ALG-125097, an siRNA drug candidate for CHB; and ALG-055009, a small molecule THR-ß agonist for NASH. The company's strategy leverages the extensive expertise of its team in liver disease and viral hepatitis to develop targeted antiviral therapies and expedite its drug development pipeline.
Ignyta is a scientifically-driven biotechnology company catalyzing personalized medicine in autoimmune diseases. Their goal is to revolutionize the quality of biomarkers and tests available to rheumatologists and patients to help them make better informed, more individualized treatment decisions; and to identify truly novel autoimmune disease targets for biopharmaceutical companies to enable the development of precise therapies for patients worldwide.
Ignyta was incorporated in 2011 and operates in San Diego, California.
Allakos Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, founded in 2012. The company specializes in developing antibody-based therapeutics aimed at treating various diseases linked to dysregulation of the T-helper type 2 immune response, including allergic diseases, inflammation, and conditions characterized by excessive inflammatory cell production. Its lead therapeutic candidate, antolimab (AK002), targets conditions such as eosinophilic gastritis, eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Additionally, Allakos is advancing another program, AK006, which targets the Siglec-6 receptor on mast cells to modulate their activity and reduce excessive activation. Through these initiatives, Allakos aims to address significant unmet medical needs in immunological health.
Viewics, Inc. offers Software as a Service (SaaS) business intelligence and analytics solutions tailored for the healthcare industry in the United States and Canada. The company provides the Viewics Data Platform, which integrates with various enterprise systems and supports multiple data formats for efficient data management. Among its key products are Viewics Health Insighter, which delivers interactive dashboards for clinical, operational, sales, and marketing teams, and Viewics Pulse, a web-based platform designed for data transparency and sharing among clients, patients, payors, and providers. These solutions facilitate operational insights, financial management, and compliance analytics, among other applications, and are utilized by a range of healthcare organizations, including clinical laboratories and hospitals. Established in 2010 and based in Sunnyvale, California, Viewics operates as a subsidiary of Roche Holding AG.
Syapse, Inc. is a company that specializes in precision medicine through its software platform, which integrates and analyzes clinical, molecular, treatment, and outcomes data. This platform supports data-driven decision-making for healthcare executives, care teams, and researchers involved in precision medicine programs. One of its key offerings is the Syapse Learning Health Network, a global data-sharing network focused on oncology, which leverages real-world data to enhance clinical decision-making. By connecting health systems, life sciences companies, and regulators, Syapse aims to accelerate the generation of real-world evidence to improve cancer patient outcomes. Founded in 2008 and headquartered in San Francisco, California, Syapse is committed to ensuring that all cancer patients receive high-quality care through improved precision medicine initiatives.
mySugr is a digital health company that simplifies life with diabetes. The mySugr App, in combination with integrated medical devices, empowers people with diabetes through a comprehensive self-management package: it includes the mySugr App (Logbook, Insulin Calculator, Diabetes Coach, Doctor Reports) and a connected blood sugar meter with home-delivered unlimited test strips. A large part of the company lives with diabetes, many since childhood.
Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases.
Vivet Therapeutics is focused on optimizing gene therapy through a partnership with the Fundacion para la Investigacion Medica Aplicada (FIMA) at the Centro de Investigación Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression.
Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains causing significant invasive pneumococcal disease and antibiotic resistance; VAX-A1, a conjugate vaccine candidate for protection against subtypes of Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was founded in 2013 and is headquartered in Foster City, California.
ForSight Labs is dedicated to developing innovative ophthalmic technologies aimed at enhancing the sight and quality of life for visually impaired patients. The organization collaborates with entrepreneurs, investors, and clinicians to drive advancements in eye care through the creation and commercialization of high-impact solutions. With millions of individuals in the U.S. suffering from vision impairment and the associated economic burden exceeding $50 billion annually, ForSight Labs addresses a significant public health challenge. Their focus includes developing treatments for conditions such as glaucoma, which can lead to irreversible blindness in adults. By fostering a creative and cooperative environment, ForSight Labs strives to deliver effective solutions to the ophthalmic community and the patients it serves.
Arch Oncology is an immuno-oncology company focused on developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. Founded in 2006 and based in St. Louis, Missouri, with a corporate office in Brisbane, California, the company aims to create innovative therapies that leverage both adaptive and innate immune responses. Arch Oncology's approach involves a new class of checkpoint inhibitors, which represents a significant advancement in cancer treatment. Through its research and development efforts, the company seeks to improve outcomes for patients battling various forms of cancer.
Viewics, Inc. offers Software as a Service (SaaS) business intelligence and analytics solutions tailored for the healthcare industry in the United States and Canada. The company provides the Viewics Data Platform, which integrates with various enterprise systems and supports multiple data formats for efficient data management. Among its key products are Viewics Health Insighter, which delivers interactive dashboards for clinical, operational, sales, and marketing teams, and Viewics Pulse, a web-based platform designed for data transparency and sharing among clients, patients, payors, and providers. These solutions facilitate operational insights, financial management, and compliance analytics, among other applications, and are utilized by a range of healthcare organizations, including clinical laboratories and hospitals. Established in 2010 and based in Sunnyvale, California, Viewics operates as a subsidiary of Roche Holding AG.
Fabric Genomics is making genomics-driven precision medicine a reality. We provide clinical decision support software that enables clinical labs, hospital systems and country-sequencing programs to gain actionable genomic insights, resulting in faster and more accurate diagnoses and reduced turnaround time. Fabric’s end-to-end genomic analysis platform incorporates proven AI algorithms, and has applications in both hereditary disease and oncology. Headquartered in Oakland, California, Fabric Genomics was founded by industry veterans and innovators with a deep understanding of bioinformatics, large-scale genomics and clinical diagnostics.
Purigen Biosystems' innovative products offer a truly transformative solution for DNA and RNA purification. Our proprietary approach uses isotachophoresis to separate nucleic acids freely in solution without binding or stripping from a physical surface. Because of this, our technology is agnostic to nucleic acid size or sequence and delivers unbiased results ― even from the more challenging sample types like FFPE tissue or low cell counts. Our Ionic Purification System and Kits combine to provide researchers with a fast, efficient and effective alternative for automated nucleic acid purification.
Second Genome’s mission is to transform lives with medicines developed through innovative microbiome science. Second Genome has built a novel platform for microbiome drug discovery. Second Genome has completed more than 400 microbiome studies, analyzing more than 75,000 samples, for internal R&D, as well as for external partners across government, academia, pharmaceutical, nutrition and industrial companies. The team leverages its microbiome analysis platform with its partners’ specific expertise to generate insightful findings that can accelerate research programs by elucidating the role of the microbiome in human health conditions, agriculture, animal health and other industries. The company has established a pipeline of therapeutic products for the treatment of inflammation and metabolic diseases.
Lumos Pharma is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to developing and commercializing therapeutics for severe, rare, and genetic diseases. Its lead candidate, LUM-201, is an oral growth hormone stimulating small molecule currently undergoing Phase 2 clinical trials for pediatric growth hormone deficiency. The company also holds a licensing agreement with Ellipses Pharma Limited to develop and commercialize nanoparticle formulations for oncology indications. Additionally, Lumos Pharma is focused on treating Creatine Transporter Deficiency, leveraging technology from the University of Cincinnati and collaborating with Key Opinion Leaders and the National Institutes of Health. Founded in 2011, Lumos Pharma aims to address unmet medical needs through innovative therapies.
MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.
Biodesy has developed a unique and highly sensitive means of detecting conformational change in proteins and other biological molecules. Our technology, based on a phenomenon called ‘second-harmonic generation’ (SHG), can monitor structural change at any site within a protein, in real time.
Tensha Therapeutics is developing small molecule bromodomain inhibitors, a new class of epigenetic modulators of gene expression, to treat cancer and other serious disorders. The company‟s programs are based on the discovery from the laboratory of Dr. James Bradner at Dana-Farber Cancer Institute of first-in-class, potent small molecule BET bromodomain inhibitors. The company‟s lead program is aimed at the treatment of patients with BRD4-NUT midline carcinoma, acute myeloid leukemias, multiple myeloma, and other diseases. Tensha is a Focused Company funded by HealthCare Ventures.
C4 is building on the knowledge with synthetic chemical compounds which it calls Degronimids. These compounds can be engineered and linked together to bind with many molecular targets that today’s drugs can’t bind with, Cohen said. The key insight, he said, is that the scientific founders have discovered a way to bind with select disease-causing proteins, and flag them as cellular trash, so that the ordinary proteasome garbage disposal system can get rid of them. Selecting the precise disease-related proteins to send to the trash is obviously critical, because any drug like this could cause serious side effects if it sent healthy proteins involved in normal cell processes to the trash. C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Our Degronimid™ platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previously thought to be undruggable, while reducing the potential for drug resistance. The broad applicability of Degronimids, and our chemical biology platform designed for accelerated validation, have the potential to make an unprecedented impact across many diseases through multiple industry collaborations as well as proprietary programs. The Company has received an exclusive worldwide license to the Degronimid platform and related IP from Dana-Farber.
Flatiron Health, Inc. is a healthcare technology company that specializes in oncology, focusing on enhancing cancer research and patient care. The company has developed a data platform that integrates and organizes clinical and financial information from electronic medical records and billing systems. This platform, known as OncologyCloud, provides valuable analytics for cancer care providers and life sciences organizations, enabling them to track treatment patterns, monitor adherence to guidelines, and identify suitable candidates for clinical trials in real-time. Flatiron Health also offers additional tools such as OncoCloud for community oncology practices, Flatiron Assist for clinical decision support, and OncoEMR to assist providers in meeting oncology care model requirements. The company collaborates with over 280 community cancer practices, several major academic research centers, and prominent oncology companies. Founded in 2012 and based in New York, Flatiron Health operates as a subsidiary of Roche Holding AG.
Atterocor, Inc. focuses on research and development of therapeutics for adrenal disease. Atterocor, Inc. was incorporated in 2012 and is based in Ann Arbor, Michigan.
They are constantly evolving better science by applying the latest advances in genomics and synthetic biology to help reduce costs, simplify workflows and improve results. Their core protein engineering technologies enable us to tailor enzymes to suit specific applications in next-generation DNA and RNA sequencing, DNA amplification and molecular diagnostics. Biomedical research is no longer limited by the constraints of native enzyme structure or function.
MacuLogix, Inc. specializes in the diagnosis, monitoring, and treatment of age-related macular degeneration (AMD), a leading cause of blindness. The company offers the AdaptDx, a fully automated dark adaptometer designed to aid eye care professionals in detecting and tracking AMD at its earliest stages, potentially up to three years before it becomes visible. This early detection capability allows for timely intervention, which can help prevent vision loss. MacuLogix markets its products through distributors in the United States and internationally, as well as online, to ensure accessibility for healthcare providers. Founded in 2008 and based in Harrisburg, Pennsylvania, MacuLogix is committed to leveraging the science of dark adaptation to combat preventable blindness associated with AMD.
Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.
Adheron Therapeutics, Inc. is focused on developing pharmaceuticals for the treatment of rheumatoid arthritis and fibrotic diseases, including pulmonary and skin fibrosis. The company is advancing its lead product, SDP051, a Cadherin-11 (Cad-11) antagonist that disrupts cell adhesion, thereby influencing protein production that can affect the cellular environment. This innovative approach aims to provide a next-generation, non-immunosuppressive treatment for fibrotic conditions and to address cartilage destruction associated with rheumatoid arthritis. Established in 2006 as Synovex Corporation, Adheron Therapeutics is based in Berkeley, California, and builds on research pioneered by Dr. Michael Brenner at Brigham and Women’s Hospital and Harvard Medical School. As of October 2015, Adheron operates as a subsidiary of Roche Holding AG.
Based in Dallas, Texas, AveXis is a clinic-ready, synthetic biology platform company. AveXis has, at its core, a desire to establish unique industry and research alliances which will bring innovative treatments to people with unmet medical needs. Our work in spinal muscular atrophy (SMA), a rare/orphan disease, is our first focus.
GeneWeave Biosciences is advancing clinical microbiology with diagnostic solutions that will enable hospitals and physicians around the world to prevent drug-resistant infections, improve antibiotic stewardship and quickly determine the optimal antibiotic therapy for critical bacterial infections. The company’s innovative and proprietary Smarticles™ technology harnesses the power of biology to enable homogeneous assays that rapidly measure bacterial drug resistance without the need for enrichment, culture, or sample preparation.
Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains causing significant invasive pneumococcal disease and antibiotic resistance; VAX-A1, a conjugate vaccine candidate for protection against subtypes of Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was founded in 2013 and is headquartered in Foster City, California.
Stratos Genomics, Inc., a DNA sequencing technology company, develops sequencing by expansion, a single-molecule detection process for genome sequencing and targeted oncology panels. It enables genome sequencing using nanopore technology, wherein a device transits through the nanopore and a distinct electrical signal of each base reporter is identified. The company was founded in 2007 and is based in Seattle, Washington. As of May 20, 2020, Stratos Genomics, Inc. operates as a subsidiary of Roche Holding AG.
mySugr is a digital health company that simplifies life with diabetes. The mySugr App, in combination with integrated medical devices, empowers people with diabetes through a comprehensive self-management package: it includes the mySugr App (Logbook, Insulin Calculator, Diabetes Coach, Doctor Reports) and a connected blood sugar meter with home-delivered unlimited test strips. A large part of the company lives with diabetes, many since childhood.
Zikani Therapeutics, Inc. develops and commercializes therapeutics for patients with limited treatment options. It offers TURBO-ZM, a platform to develop novel ribosome modulating agents (RMAs) for the treatment of cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Zikani Therapeutics, Inc. was formerly known as Macrolide Pharmaceuticals, Inc. and changed its name to Zikani Therapeutics, Inc. in February 2015. Zikani Therapeutics, Inc. was incorporated in 2014 and is based in Watertown, Massachusetts.
Signature Diagnostics GmbH is a translational oncology and genomics company based in Potsdam, Germany, founded in 2004. The company specializes in the development of extensive biobanks comprising blood plasma and tumor tissue samples from cancer patients, particularly focusing on colorectal and lung cancers through multicenter prospective clinical studies. Signature Diagnostics also creates next-generation sequencing assays utilizing targeted gene panels and demonstrates expertise in ultra-deep sequencing tests that leverage circulating free DNA (cfDNA). These advancements aim to enhance non-invasive monitoring of treatment responses in cancer patients. Additionally, Signature has developed molecular oncology diagnostic products for early cancer detection and prognosis, which have been launched from its ISO 15189 certified service laboratory. The company collaborates with various clinical, pharmaceutical, and diagnostic partners to further its research and product development initiatives. As of February 2015, it operates as a subsidiary of Roche Holding AG.
Lysosomal Therapeutics, Inc. is focused on discovering and developing small-molecule therapies aimed at treating severe neurological diseases, including Gaucher-related neurodegeneration and Parkinson’s disease. Founded in 2011 and based in Cambridge, Massachusetts, the company utilizes a research strategy that capitalizes on the established connection between lysosomal disorders and neurodegenerative conditions. This approach supports the development of innovative treatment options for patients affected by movement, cognition, and overall health issues related to these diseases. By leveraging clinically validated insights, Lysosomal Therapeutics aims to create effective therapies to address the unmet medical needs in the field of neurodegeneration.
Trophos is a clinical stage pharmaceutical company developing innovative therapeutics for indications with under-served needs in neurology and cardiology. Trophos is a fully integrated clinical stage company with a pipeline of original molecules in development for the motoneuron diseases amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and spinal muscular atrophy (SMA), chemotherapy-induced peripheral neuropathy, cardiac ischemia-reperfusion injury and other neurological conditions.
Foundation Medicine, Inc. specializes in providing molecular information products aimed at enhancing cancer treatment through genomic insights. The company utilizes proprietary methods and algorithms to analyze cancer specimens, helping physicians tailor treatments based on the unique genetic profile of each patient's tumor. Its product offerings include FoundationOne for solid tumors, FoundationOne Heme for hematologic malignancies, and various diagnostic assays such as FoundationFocus CDxBRCA for ovarian cancer. Additionally, Foundation Medicine develops a knowledgebase called FoundationCORE to disseminate scientific advancements within the oncology community. The company collaborates with major pharmaceutical firms and research organizations to advance precision medicine and develop companion diagnostics. Founded in 2009 and headquartered in Cambridge, Massachusetts, Foundation Medicine operates as a subsidiary of Roche Holdings, Inc. It aims to transform cancer care by enabling personalized treatment strategies informed by detailed genomic profiling.
Based in Dallas, Texas, AveXis is a clinic-ready, synthetic biology platform company. AveXis has, at its core, a desire to establish unique industry and research alliances which will bring innovative treatments to people with unmet medical needs. Our work in spinal muscular atrophy (SMA), a rare/orphan disease, is our first focus.
CytomX Therapeutics is an early stage, privately-funded biotechnology company developing Probodiesâ„¢, proteolytically-activated antibodies. Probodies, by their ability to site-direct the activity of antibodies, will result in an improved therapeutic index for validated targets as well enable the drugging of targets with broad tissue expression. Their mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.
Bina Technologies focuses on enhancing personalized healthcare through advanced data analytics. The company has developed a big data science platform that provides scalable genomic analytics tailored for researchers and clinicians. This platform enables centralized management and processing of next-generation sequencing (NGS) data, facilitating insights for both academic and translational research. By significantly reducing the time, cost, and complexity involved in extracting knowledge from genomic data, Bina Technologies aims to transform the landscape of medicine and support the future of data-driven healthcare.
Dutalys is a privately owned biotechnology company located in Vienna, Austria, established in April 2010. The company focuses on the discovery and development of human antibodies, specifically bi-specific and monoclonal antibodies, which are utilized in pharmaceutical and therapeutic applications. Dutalys has received support through seed financing and research grants from various Austrian institutions, including Austria Wirtschaftsservice, the Austrian Research Promotion Agency, and the Technology Agency of the City of Vienna, as well as funding from the Austrian Academic Business Incubator.
Ariosa Diagnostics, based in San Jose, California, is a molecular diagnostics company specializing in prenatal testing for fetal health. The company offers blood tests that assess the risk of common fetal chromosome conditions, providing crucial information for expectant mothers. Utilizing proprietary technology, Ariosa Diagnostics enables targeted analysis of DNA, facilitating accurate and reliable assessments of fetal health risks.
Curetis N.V. is a commercial-stage molecular diagnostics company based in Holzgerlingen, Germany, specializing in solutions for severe infectious diseases. The company develops and manufactures a range of molecular microbiology products aimed at detecting various pathogens, including bacteria and fungi, as well as identifying genetic markers for antimicrobial resistance. Key offerings include the Unyvero L4 Lysator for sample pre-processing, the Unyvero A50 Analyzer, and the Unyvero C8 Cockpit, which serves as a control panel for these devices. Curetis also provides Unyvero Application Cartridges for syndromic infectious disease testing and the ARES AMR Database, which compiles data on antimicrobial resistance genetics. Its tests cover multiple infections, including pneumonia and urinary tract infections. Founded in 2007, Curetis has established strategic partnerships with companies like MGI Tech Co. Ltd. and Qiagen N.V., enhancing its capabilities in the molecular diagnostics market.
Aileron Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing a novel class of drugs known as stabilized cell-permeating alpha-helical peptides, particularly in the field of oncology. The company’s lead drug candidate, ALRN-6924, is currently undergoing multiple clinical trials, including Phase 2a studies for advanced solid tumors and peripheral T-cell lymphoma, as well as Phase 1 trials for acute myeloid leukemia and advanced myelodysplastic syndrome. Aileron is also working on a next-generation wild type p53 reactivator. Collaborations with notable institutions, such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer, further enhance its research efforts, particularly in evaluating ALRN-6924 in combination therapies. Aileron Therapeutics was founded in 2001, originally named Renegade Therapeutics, and is headquartered in Watertown, Massachusetts.
Allakos Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, founded in 2012. The company specializes in developing antibody-based therapeutics aimed at treating various diseases linked to dysregulation of the T-helper type 2 immune response, including allergic diseases, inflammation, and conditions characterized by excessive inflammatory cell production. Its lead therapeutic candidate, antolimab (AK002), targets conditions such as eosinophilic gastritis, eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Additionally, Allakos is advancing another program, AK006, which targets the Siglec-6 receptor on mast cells to modulate their activity and reduce excessive activation. Through these initiatives, Allakos aims to address significant unmet medical needs in immunological health.
Allakos Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, founded in 2012. The company specializes in developing antibody-based therapeutics aimed at treating various diseases linked to dysregulation of the T-helper type 2 immune response, including allergic diseases, inflammation, and conditions characterized by excessive inflammatory cell production. Its lead therapeutic candidate, antolimab (AK002), targets conditions such as eosinophilic gastritis, eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Additionally, Allakos is advancing another program, AK006, which targets the Siglec-6 receptor on mast cells to modulate their activity and reduce excessive activation. Through these initiatives, Allakos aims to address significant unmet medical needs in immunological health.
InterMune is a biotechnology company dedicated to the research, development, and commercialization of therapies aimed at treating pulmonary and orphan fibrotic diseases. The company primarily focuses on idiopathic pulmonary fibrosis (IPF), a progressive and serious lung condition. Its flagship product, Pirfenidone, is the first medication approved for IPF globally, marketed in the European Union under the brand name Esbriet®. InterMune is actively conducting a Phase 3 clinical trial to seek regulatory approval for this treatment in the United States. Additionally, the company is engaged in research initiatives to discover targeted small-molecule therapeutics and biomarkers for serious pulmonary and fibrotic diseases. Beyond pulmonology, InterMune also has products approved for treating severe conditions such as malignant osteopetrosis and chronic granulomatous disease, indicating a diverse therapeutic focus.
Santaris Pharma A/S is a clinical-stage biopharmaceutical company specializing in RNA-targeted therapies. Founded in 2003 and headquartered in Denmark, the company utilizes its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine to develop single-stranded LNA-based drug candidates for various diseases. Its research focuses on infectious diseases and cardiometabolic disorders, while also addressing cancer, cardiovascular diseases, inflammatory diseases, and rare genetic disorders through collaborations with major pharmaceutical firms. Santaris Pharma has established partnerships with organizations such as miRagen Therapeutics, Shire, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. The company holds exclusive worldwide rights to manufacture and sell products containing LNA as an active ingredient, which supports its goal of obtaining marketing approval for its innovative therapies.
Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.
As the genomics community pushes toward the $1,000 genome, Genia is looking beyond, to the $100 genome, bringing the benefits of genome sequencing out of the lab and into the everyday world. Genia's technology is based on Biological Nanopores: Structure-Based Sequencing of Single DNA Molecules. We aim to reduce the price of sequencing and increase speed, accuracy, and sensitivity by moving away from amplification, complicated fluidics, and optical detection. Genia Technologies, Inc. is a private company located in Mountain View, CA. Genia was founded in March, 2009. The company recently closed its Series A round with a publicly held global biotech company.
Stratos Genomics, Inc., a DNA sequencing technology company, develops sequencing by expansion, a single-molecule detection process for genome sequencing and targeted oncology panels. It enables genome sequencing using nanopore technology, wherein a device transits through the nanopore and a distinct electrical signal of each base reporter is identified. The company was founded in 2007 and is based in Seattle, Washington. As of May 20, 2020, Stratos Genomics, Inc. operates as a subsidiary of Roche Holding AG.
Lysosomal Therapeutics, Inc. is focused on discovering and developing small-molecule therapies aimed at treating severe neurological diseases, including Gaucher-related neurodegeneration and Parkinson’s disease. Founded in 2011 and based in Cambridge, Massachusetts, the company utilizes a research strategy that capitalizes on the established connection between lysosomal disorders and neurodegenerative conditions. This approach supports the development of innovative treatment options for patients affected by movement, cognition, and overall health issues related to these diseases. By leveraging clinically validated insights, Lysosomal Therapeutics aims to create effective therapies to address the unmet medical needs in the field of neurodegeneration.
Alios is discovering and developing novel therapeutic agents based on three platform technologies including: small molecule activators of innate immunity antiviral pathways (RNase L activation), phosphate protected nucleotide prodrug chemistry, and glycoprotein-engineering of interferons (Glycoferonâ). This complementary group of platform technologies has the potential to generate a number of distinct therapeutic products to treat a variety of serious viral infections such as chronic hepatitis B and C, HIV infection, and respiratory viruses (e.g. pandemic influenza) and emerging viral diseases (e.g. SARS).
IQuum, founded in 1998 in the Boston metropolitan area, specializes in biological sample testing technology aimed at enhancing healthcare and daily life through advancements in genomics and biotechnology. The company has developed a novel lab-in-a-tube platform that features a closed sample tube and a modular sample processor architecture. This innovative system allows for rapid and user-friendly testing of biological samples, performing multiple assays in an "insert-and-test" format that streamlines the entire process from sample collection to result interpretation. IQuum's platform addresses the growing market demand for comprehensive information extraction from biological samples, and the company is focused on advancing the next generation of testing systems based on this technology. Additionally, IQuum provides services related to clinical diagnostics, therapeutic monitoring, and biodefense.